BioWorld

March 17, 2008

Transition Could Get $130M in Diabetes Deal With Lilly

Transition Therapeutics Inc. could receive up to $137 million in a deal with drug giant Eli Lilly and Co., which will acquire rights to Transition's gastrin-based therapies for diabetes. (BioWorld Today) Read More

Legislation Would Create Path for Follow-on Biologics Work

T-Cell Gene is Linchpin for Breast Cancer Metastasis

Investigations Looming in Off-Label Promotion

Corrections & Clarifications

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...